SecBot SecBot
PRESS-RELEASE ·Filed Apr 17, 2026

ZYME

Zymeworks Inc.
BULLISH
Impact 7/10
Horizonweeks Processed7mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The breadth of preclinical data strengthens Zymeworks' ADC platform narrative, which could attract partnership interest and re-rate the stock ahead of the ZW191 oral data readout. Traders should monitor for clinical validation of the pan-RASi payload strategy, especially in RAS-mutant cancers with high unmet need.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$27.80
T+0 close · Apr 17, 2026 · via day close
Latest settled
−11.29%
T+60 · $24.66
Vs SPY
−17.44%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 17 $27.80entry
  2. T+1 · 7mo ago +0.18%α +0.37% · $27.85
  3. T+5 · 7mo ago +1.08%α +0.52% · $28.10
  4. T+20 · 6mo ago −13.81%α −19.18% · $23.96
  5. T+60 · 4mo ago −11.29%α −17.44% · $24.66
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Zymeworks announced six preclinical poster presentations at AACR 2026 showcasing its next-generation antibody-drug conjugate (ADC) programs, including first-in-class pan-RAS inhibitor ADCs targeting solid tumors. New data highlight efficacy, tumor-selective delivery, and favorable tolerability across multiple programs. An oral presentation on Phase 1 data for ZW191 will follow on April 21.

Key Facts

  • Six poster presentations at AACR 2026 feature preclinical data from Zymeworks' ADC and payload development programs.
  • Programs include first-in-class pan-RAS inhibitor ADCs targeting Ly6E, CLDN18.2, PTK7, and FRα.
  • ZW191 Phase 1 clinical data to be presented orally on April 21, 2026, from the first-in-human trial in advanced solid tumors.
  • Preclinical data show strong anti-tumor activity at low doses (as low as 1 mg/kg), favorable tolerability, and potential for combination therapy.
  • Novel eIF4A inhibitor payloads demonstrated robust anti-tumor activity across multiple targets, representing a new ADC payload class.

Financial Impact

Potential long-term value creation through pipeline expansion and platform validation; no immediate revenue impact.

pipeline valueR&D valuationinvestor sentimentpartnership potential

Risk Factors

  • Preclinical data may not translate to clinical efficacy.
  • ZW191 Phase 1 data could show safety or tolerability concerns.
  • Competition in the ADC and RAS inhibitor space is intensifying.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3276454

Track record

25 reports on ZYME

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +16.72% at T+60 after the Jun 14, 2026 report. 8 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today 8-K Neutral 4/10 Entry price pending
  2. Nov 16, 2026today Press Release Neutral 4/10 Entry price pending
  3. Nov 13, 20263d ago 144 Neutral 2/10 Entry $26.24 Now $26.24 −0.00% settles Dec 14
  4. Nov 9, 20267d ago 8-K/A Neutral 5/10 Entry $31.46 Now $26.24 −16.59% settles Dec 9
  5. Nov 9, 20267d ago Press Release Bullish 6/10 Entry $31.46 Now $26.24 −16.59% settles Dec 9
  6. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $30.94 Now $26.24 −15.19% settles Dec 3
  7. Oct 26, 202621d ago DEFA14A Neutral 2/10 Entry $28.85 Now $26.24 −9.05% settles Nov 24
  8. Oct 26, 202621d ago DEF 14A Neutral 3/10 Entry $28.85 Now $26.24 −9.05% settles Nov 24
  9. Oct 23, 202624d ago 8-K Bullish 7/10 Entry $28.22 Now $26.24 −7.02% settles Nov 20
  10. Oct 15, 20264w ago Press Release Neutral 1/10 Entry $25.75 to $29.07 Now $26.24 +1.90% ▲ +12.89% +14.31% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens Wed (12h 44m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 17, 2026